title: Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
abstract: Thrombocytopenia is a significant problem for patients receiving prolonged or aggressive chemotherapy for malignancy. For carboplatin, it is the predominant dose-limiting toxicity and it is cumulative in nature. A number of agents have been evaluated for efficacy in reducing the problem of thrombocytopenia. Some have proved valueless and have been discarded. Others (eg, recombinant thrombopoietin) are under current study, and one (interleukin-11 or oprelvekin) is now commercially available. In addition, the currently available cytoprotectant, amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA), has been shown to reduce the severity and duration of thrombocytopenia caused by carboplatin. Because of the short half-life of amifostine relative to that of carboplatin, multiple doses of amifostine have been administered in conjunction with carboplatin. The optimal dosing regimen with amifostine and carboplatin needs to be further evaluated in clinical studies. Future trials will also expand these observations to carboplatin-containing combination chemotherapy regimens and will further define the role of amifostine as a multilineage bone marrow protectant. The ability of amifostine to demonstrate multilineage bone marrow protection differentiates it from currently available growth factors and fulfills a medical need, including reducing the need for platelet transfusions and maintaining the desired chemotherapy dose intensity.
authors.affiliation: Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: G T
authors.initials: GT
authors.lastname: Budd
authors.forename: R
authors.initials: R
authors.lastname: Ganapathi
authors.forename: L
authors.initials: L
authors.lastname: Wood
authors.forename: J
authors.initials: J
authors.lastname: Snyder
authors.forename: D
authors.initials: D
authors.lastname: McLain
authors.forename: R M
authors.initials: RM
authors.lastname: Bukowski
mesh_terms: D004999:Amifostine / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D019610:Cytoprotection; D006801:Humans; D017713:Platelet Transfusion; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000517:prevention & control*; D013926:Thrombopoietin / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D020011:Protective Agents; D013926:Thrombopoietin; D016190:Carboplatin; D004999:Amifostine